ARQL News and Press, ArQule Inc. From 07/13/19

by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...

ArQule (NASDAQ: ARQL), a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases, recently closed its underwritten public offering of 10,637,500 shares of common stock, which includes 1,387,500 shares representing the over-a...

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...

Shares of ArQule ( ARQL ) have risen by over 50% since my last update piece stated it remained a Buy with substantial upside ahead over the long term. Readers may be tempted to take full profits on the name considering the high appreciation that's taken place recently. However, when thesis str...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

This is a special contribution article by Prof. Grant Henning based on his published research on the BLM technical theory . The model, his trailing stop-loss approach, and comments are expressly based on his own proprietary methodology and forecasts in the references below. Winning Bounc...

ArQule ( ARQL ) is an important biotech to watch, that's because it had a huge update on a mid-stage study, showing positive results in patients with rare diseases known as PIK3CA-related Overgrowth Spectrum or PROS and proteus syndrome ((PS)). This is a solid speculative biotech. The reason w...

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public offering price of $9.75 per share. The ...

Time is the friend of the wonderful company, the enemy of the mediocre. - Warren Buffett Aside from his prowess for numbers, Warren Buffett has the excellent temperament for investment. In my view, Buffett's mega success is the cumulation of his hard work and rigorous learning. With a vora...

ArQule (NASDAQ: ARQL ) has priced its public offering of 9,250,000 common shares at $9.75 per share, for gross proceeds of ~$90.2M. More news on: ArQule, Inc., Healthcare stocks news, Read more ...